Bausch & LombBLCO +2.58%77 EBITDA Margin % is 10.77% as of Mar. 2026, which is 39% below its 10-year median of 17.67. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.60 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Bausch & Lomb ranks better than 59.93% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bausch & Lomb's EBITDA for the
three
months ended in Mar. 2026 was $134 Mil. Bausch & Lomb's Revenue for the
three
months ended in Mar. 2026 was $1,244 Mil. Therefore, Bausch & Lomb's EBITDA margin for the quarter that ended in Mar. 2026 was 10.77%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bausch & Lomb EBITDA Margin % Related Terms
Bausch & Lomb EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLCO vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a EBITDA Margin % of 10.77% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bausch & Lomb and its competitors. This is 39% below median its historical median of 17.67. Over the past decade, Bausch & Lomb's EBITDA Margin % has ranged from 10.29 to 25.16. According to the industry distribution chart, Bausch & Lomb ranks #327 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 40.1%.
Is Bausch & Lomb's EBITDA Margin % too high?
Bausch & Lomb's current EBITDA Margin % of 10.77% is 39% below median its 10-year median of 17.67. Over the past 10 years, this metric has ranged from a low of 10.29 to a high of 25.16. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Bausch & Lomb's value of 10.77% is 44.1% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #327 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #327 out of 816 companies for EBITDA Margin %. This puts Bausch & Lomb in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Bausch & Lomb's value of 10.77% is 44.1% above this benchmark. Historically, Bausch & Lomb's own EBITDA Margin % has ranged from 10.29 to 25.16 over the past decade. While the company's 10-year median is 17.67 vs. the industry median of 7.48, Bausch & Lomb has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current EBITDA Margin % of 10.77% is 44.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current EBITDA Margin % is 10.77%, which is 39% below median its own 10-year median of 17.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.60, compared to a current price of $15.91 — trading 14.5% below its estimated fair value. The current EBITDA Margin % is 10.77%, which is 39% below median its 10-year median of 17.67 and 44.1% above the Medical Devices & Instruments industry median of 7.48. Bausch & Lomb's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current EBITDA Margin % is 10.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $15.91 is trading 14.5% below its estimated GF Value™ of $18.60.
GuruFocus considers Bausch & Lomb to be Modestly Undervalued.
Key valuation signals for BLCO:
EBITDA Margin %: 10.77% (39% below median its 10-year median of 17.67)
GF Value™: $18.60 vs. price of $15.91 (14.5% below fair value)
Industry Position: 44.1% above the Medical Devices & Instruments median (#327 of 816)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
